tradingkey.logo

Cibus Inc

CBUS
View Detailed Chart
1.370USD
-0.075-5.19%
Market hours ETQuotes delayed by 15 min
71.90MMarket Cap
LossP/E TTM

Cibus Inc

1.370
-0.075-5.19%
Intraday
1m
30m
1h
D
W
M
D

Today

-5.19%

5 Days

-16.97%

1 Month

-4.86%

6 Months

-39.11%

Year to Date

-50.72%

1 Year

-68.86%

View Detailed Chart

TradingKey Stock Score of Cibus Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cibus Inc's Score

Industry at a Glance

Industry Ranking
142 / 210
Overall Ranking
345 / 4617
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
14.400
Target Price
+800.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cibus Inc Highlights

StrengthsRisks
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 2614.65% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.26M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.26M.
Overvalued
The company’s latest PE is -0.14, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.60M shares, decreasing 0.28% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 856.15K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.12.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Cibus Inc Info

Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
Ticker SymbolCBUS
CompanyCibus Inc
CEODr. Peter Ronald Beetham, Ph.D.
Websitehttps://www.cibus.com/
KeyAI